Cargando…
Biomedical Prevention: State of the Science
Preexposure prophylaxis (PrEP) and treatment as prevention (TasP) involve the use of antiretroviral (ARV) drugs by human immunodeficiency virus (HIV)-negative and -positive individuals to reduce HIV acquisition and transmission, respectively. Clinical science has delivered a consistently high effect...
Autores principales: | McCormack, Sheena M., Gafos, Mitzy, Desai, Monica, Cohen, Myron S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060254/ https://www.ncbi.nlm.nih.gov/pubmed/24926033 http://dx.doi.org/10.1093/cid/ciu297 |
Ejemplares similares
-
Leveraging HIV Treatment to End AIDS, Stop New HIV Infections, and Avoid the Cost of Inaction
por: Sidibé, Michel, et al.
Publicado: (2014) -
Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence
por: Amico, K. Rivet, et al.
Publicado: (2014) -
Clinician Perspectives on Delaying Initiation of Antiretroviral Therapy for Clinically Eligible HIV-Infected Patients
por: Beer, Linda, et al.
Publicado: (2015) -
Association of HIV/AIDS Clinician Warm Line Utilization with Diagnosis and Management of Antiretroviral Treatment Failure in Mozambique: A Retrospective Analysis of Program Data
por: Ruano Camps, Maria, et al.
Publicado: (2017) -
High HIV prevalence and incidence among women in Southern Mozambique: Evidence from the MDP microbicide feasibility study
por: Mocumbi, Sibone, et al.
Publicado: (2017)